Palliation of pelvic and head and neck cancer with paclitaxel and a novel radiotherapy regimen

Journal of Palliative Medicine

Volumn 10, Issue 4, 2007, Pages 877-881

  Carrascosa, Luis A ^a   Yashar, Catheryn M ^b   Paris, Kristie J ^a   Larocca, Renato V ^c   Faught, Samuel Ryan ^a   Spanos, William J ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Kentuckiana Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MALE; MUCOSA INFLAMMATION; PALLIATIVE THERAPY; PELVIS CANCER; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PALLIATIVE CARE; PROSPECTIVE STUDIES; SURVIVAL RATE; UNITED STATES;

EID: 34848878641     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2006.0192     Document Type: Article

References (21)

1. Boulware RJ, Caderao JB, Delclos L, et al. Whole pelvis mega voltage irradiation with single doses of 1000 rad to palliate advanced gynecologic cancer. Int J Radiat Oncol Biol Phys 1979;5:333-338.
2. Spanos WJ, Wasserman T, Meoz R, et al. Palliation of advanced pelvic malignant disease with large fraction pelvic radiation and misonidazole: Final report of RTOG Phase I/II study. Int J Radiat Oncol Biol Phys 1987;13:1479-1482.
3. Spanos W, Guse C, Perez C, et al. Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: Preliminary report of RTOG 8502. Int J Radiat Oncol Biol Phys 1989;17:659-662.
4. Spanos WJ, Perez CA, Marcus S, et al. Effect of rest interval on tumor and normal tissue response - A report of Phase III Study of accelerated split course palliative radiation for advanced pelvic malignancies (RTOG 8502). Int J Radiat Oncol Biol Phys 1993;25:399-403.
5. Spanos WJ, Clery M, Perez CA, et al. Late effect of multiple daily fraction palliation schedule for advanced pelvic malignancies (RTOG 8502). Int J Radiat Oncol Biol Phys 1994;29:961-967.
6. Paris KJ, Spanos WJ, Lindberg RD, et al. Phase I-II study of multiple daily fractions for palliation of advanced head and neck malignancies. Int J Radiat Oncol Biol Phys 1992 25:657-660.
7. Keys HM, Bundy BN, Stehman FB, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: A randomized trial of the Gynecologic Oncology Group. Gynecol Oncol, 2003;89:343-353
8. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18:1606-1613.
9. Douglass HO, Moertel CG, Mayer RJ, et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986;315:1294.
10. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210-1215.
11. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-1348.
12. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-1153.
13. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;40:1137-1143.
14. Lojun SL, Sigdestad CP, Connor AM, et al. Murine intestinal crypt survival after combined taxol plus radiation exposure. Gynecol Oncol 1996;63:180-183.
15. Elomaa L, Joensuu H, Kulmala J, et al. Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer. Acta Otolaryngol 1995;115:340-344.
16. Safran H, Rathore R: Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer. Crit Rev Oncol Hematol 2002;43:57-62.
17. Chen MD, Paley PJ, Potish RA, et al. Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. Gynecol Oncol 1997;67:131-136.
18. Preisler VK, Stopper H, Schindler D, et al. Cytotoxic and genotoxic effects of paclitaxel (Taxol) and radiation in a squamous cell carcinoma cell line of the larynx. Acta Otolaryngol 1998;118:600-605.
19. Choy H, Rodriguez FF, Koester S, et al. Investigation of taxol as a potential radiation sensitizer. Cancer 1993; 71:3774-3778.
20. Tishler RB, Schiff PB, Geard CR, et al. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992;22:613-617.
21. Steren A, Sevin BU, Perras J, et al. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 1993;48:252-258.